Create Account | Sign In: Author or Forum

News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    



Category: Cardiology | Family Medicine | Internal Medicine | Nursing | Pharmacy | Conference News

Back to Journal Articles

AHA: Single AMG145 Dose Lowers LDL-Cholesterol Levels

Last Updated: November 14, 2011.


AMG145 lowers LDL-C, total cholesterol, apo-B, but has no effect on triglycerides, HDL-C, apo-A1

Share |

Comments: (0)



A single dose of AMG145 lowers low-density lipoprotein-cholesterol, total cholesterol, apolipoprotein-B levels, and suppresses unbound pro-protein convertase subtilisin/kexin type 9, according to a study presented at the American Heart Association's Scientific Sessions 2011, held from Nov. 12 to 16 in Orlando, Fla.

MONDAY, Nov. 14 (HealthDay News) -- A single dose of AMG145 lowers low-density lipoprotein-cholesterol (LDL-C), total cholesterol, apolipoprotein (apo)-B levels, and suppresses unbound pro-protein convertase subtilisin/kexin type 9 (PCSK9), according to a study presented at the American Heart Association's Scientific Sessions 2011, held from Nov. 12 to 16 in Orlando, Fla.

Clapton Dias, Ph.D., from Amgen Inc. in Thousand Oaks, Calif., and colleagues investigated whether AMG145 lowered circulating LDL-C levels. Healthy individuals, aged 18 to 45 years, with LDL-C ranging from 100 to 190 mg/dL, body mass index within 18 to 32 kg/m², and no co-medications 14 days before inclusion were randomized to receive either AMG145 or placebo. Five cohorts received subcutaneous doses and two cohorts received intravenous doses. The primary end point was the measurement of safety and tolerability after a single dose.

The investigators found that, compared to placebo, a single AMG145 dose lowered the mean LDL-C by up to 64 percent. The extent to which LDL-C was lowered, time to nadir, and duration of LDL-C lowering each had a dose-dependent relationship. AMG145 also lowered total cholesterol and apo-B. Serum triglycerides, high-density lipoprotein-cholesterol and apo-A1 were not affected by AMG145. Serum unbound PCSK9 was potently suppressed by AMG145, and this dose-response decrease correlated well with the decreases in LDL-C, total cholesterol, and apo-B. Treatment-emergent adverse event incidence was similar between patients treated with AMG145 or placebo, with no AMG145 dose correlation. There were no serious adverse events or study discontinuations due to an adverse event.

"AMG145 decreased unbound PCSK9 levels and lowered circulating LDL-C, total cholesterol, and apo-B," the authors write.

All of the study authors disclosed financial relationships with Amgen Inc., manufacturer of AMG145.

More Information

Copyright © 2011 HealthDay. All rights reserved.

Previous: SfN: Exercise Tied to Neuronal Changes in Fibromyalgia Next: Pentavalent Rotavirus Vaccine Effective in Two, Three Doses

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion:





Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)



Useful Sites
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.